# SAFETY DATA SHEET

## 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

**Product Identifier**

<table>
<thead>
<tr>
<th>Material Name:</th>
<th>Exemestane Tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade Name:</td>
<td>Aromasin; Aromasine; Exemestane Pfizer</td>
</tr>
<tr>
<td>Chemical Family:</td>
<td>Mixture</td>
</tr>
</tbody>
</table>

**Relevant Identified Uses of the Substance or Mixture and Uses Advised Against**

**Intended Use:** Pharmaceutical product used as Antineoplastic

**Details of the Supplier of the Safety Data Sheet**

<table>
<thead>
<tr>
<th>Pfizer Inc</th>
<th>Pfizer Ltd</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer Pharmaceuticals Group</td>
<td>Ramsgate Road</td>
</tr>
<tr>
<td>235 East 42nd Street</td>
<td>Sandwich, Kent</td>
</tr>
<tr>
<td>New York, New York 10017</td>
<td>CT13 9NJ</td>
</tr>
<tr>
<td>1-800-879-3477</td>
<td>United Kingdom</td>
</tr>
<tr>
<td></td>
<td>+00 44 (0)1304 616161</td>
</tr>
</tbody>
</table>

**Emergency telephone number:**

<table>
<thead>
<tr>
<th>CHEMTREC (24 hours): 1-800-424-9300</th>
<th>Emergency telephone number:</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="mailto:Pfizer-MSDS@pfizer.com">Pfizer-MSDS@pfizer.com</a></td>
<td>International CHEMTREC (24 hours): +1-703-527-3887</td>
</tr>
</tbody>
</table>

## 2. HAZARDS IDENTIFICATION

**Classification of the Substance or Mixture**

**GHS - Classification**

- Reproductive Toxicity: Category 1B
- Acute aquatic toxicity: Category 2
- Chronic aquatic toxicity: Category 2

**Label Elements**

**Signal Word:** Danger

**Hazard Statements:**

- H360FD - May damage fertility. May damage the unborn child.
- H411 - Toxic to aquatic life with long lasting effects

**Precautionary Statements:**

- P202 - Do not handle until all safety precautions have been read and understood
- P281 - Use personal protective equipment as required
- P308 + P313 - IF exposed or concerned: Get medical attention/advice
- P405 - Store locked up
- P501 - Dispose of contents/container in accordance with all local and national regulations
Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exemestane</td>
<td>107868-30-4</td>
<td>Not Listed</td>
<td>Repr.1B (H360FD) Aquatic Acute 2 (H401) Aquatic Chronic 2 (H411)</td>
<td>25</td>
</tr>
<tr>
<td>Silica colloidal, Ph. Eur.</td>
<td>112945-52-5</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>9004-34-6</td>
<td>232-674-9</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>200-334-9</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Titanium dioxide</td>
<td>13463-67-7</td>
<td>236-675-5</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crosspovidone</td>
<td>9003-39-8</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Hydroxypropyl methylcellulose</td>
<td>9004-65-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Mannitol</td>
<td>69-65-8</td>
<td>200-711-8</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Methylparaben</td>
<td>99-76-3</td>
<td>202-785-7</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Macrogol 6000</td>
<td>Not assigned</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Polysorbate 80</td>
<td>9005-65-6</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Polyvinyl alcohol</td>
<td>9002-89-5</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium starch glycolate</td>
<td>9063-38-1</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Simethicone emulsion</td>
<td>67762-90-7</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium carbonate</td>
<td>39409-82-0</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16
4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
7. HANDLING AND STORAGE

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Refer to Section 12 - Ecological Information, for information on potential effects on the environment. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Exemestane

Pfizer OEL TWA-8 Hr: 8 µg/m³

Silica colloidal, Ph. Eur.

- Austria OEL - MAKs: 4 mg/m³
- Germany (DFG) - MAK: 4 mg/m³
- Switzerland OEL -TWAs: 4 mg/m³

Magnesium stearate

- Lithuania OEL - TWA: 5 mg/m³
- Sweden OEL - TWAs: 5 mg/m³

Microcrystalline cellulose

- ACGIH Threshold Limit Value (TWA): 10 mg/m³
- Australia TWA: 10 mg/m³
- Belgium OEL - TWA: 10 mg/m³
- Estonia OEL - TWA: 10 mg/m³
- France OEL - TWA: 10 mg/m³
- Ireland OEL - TWAs: 10 mg/m³
- Latvia OEL - TWA: 2 mg/m³
- OSHA - Final PELS - TWAs: 15 mg/m³
- Portugal OEL - TWA: 10 mg/m³
- Romania OEL - TWA: 10 mg/m³
- Russia OEL - TWA: 6 mg/m³
- Spain OEL - TWA: 10 mg/m³
- Switzerland OEL -TWAs: 3 mg/m³
- Vietnam OEL - TWAs: 10 mg/m³
- Sweden OEL - TWAs: 5 mg/m³

Sucrose

- ACGIH Threshold Limit Value (TWA): 10 mg/m³
- Australia TWA: 10 mg/m³
- Belgium OEL - TWA: 10 mg/m³
- Bulgaria OEL - TWA: 10.0 mg/m³
- Estonia OEL - TWA: 10 mg/m³
- France OEL - TWA: 10 mg/m³
- Ireland OEL - TWAs: 10 mg/m³
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands: Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes: Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin: Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)
### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)

### 9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Material Name: Exemestane Tablets</th>
<th>Physical State: Tablets</th>
<th>Color: Off-white to gray</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odor: No data available.</td>
<td>Odor Threshold: No data available.</td>
<td>Molecular Weight: Mixture</td>
</tr>
<tr>
<td>Molecular Formula: Mixture</td>
<td>Solvent Solubility: No data available</td>
<td>Water Solubility: No data available</td>
</tr>
<tr>
<td>pH: No data available.</td>
<td>Melting/Freezing Point (°C): No data available</td>
<td>Boiling Point (°C): No data available.</td>
</tr>
<tr>
<td>Partition Coefficient: (Method, pH, Endpoint, Value)</td>
<td>Exemestane</td>
<td>Measured 7 Log P 2.5</td>
</tr>
</tbody>
</table>

**Silica colloidal, Ph. Eur.**
No data available

**Crosپovidone**
No data available

**Magnesium carbonate**
No data available

**Magnesium stearate**
No data available

**Mannitol**
No data available

**Microcrystalline cellulose**
No data available

**Methylparaben**
No data available

**Macrogol 6000**
No data available

**Polysorbate 80**
No data available

**Polyvinyl alcohol**
No data available

**Sodium starch glycolate**
No data available

**Sucrose**
No data available

**Simethicone emulsion**
No data available

**Hydroxypropyl methylcellulose**
No data available

**Titanium dioxide**
No data available

**Decomposition Temperature (°C):** No data available.

**Evaporation Rate (Gram/s):** No data available

**Vapor Pressure (kPa):** No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammability:
- Autoignition Temperature (Solid) (°C): No data available
- Flammability (Solids): No data available
- Flash Point (Liquid) (°C): No data available
- Upper Explosive Limits (Liquid) (% by Vol.): No data available
- Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions:
- Oxidizing Properties: No data available
- Conditions to Avoid: None known
- Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
- Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: There are no data for this formulation. The remaining information describes the potential hazards of the individual ingredients.
Short Term: May cause minimal eye irritation (based on animal data). Active ingredient is not a skin irritant. Active ingredient is not a skin sensitizer. Not acutely toxic (based on animal data).
Long Term: Animal studies have shown a potential to cause adverse effects on the fetus. Repeat-dose studies in animals have shown a potential to cause adverse effects on reproductive system.
Known Clinical Effects: Adverse effects associated with therapeutic use include hot flashes, nausea, fatigue, increased sweating, increased appetite, asthenia, and fever.

Acute Toxicity: (Species, Route, End Point, Dose)

Exemestane
- Rat Oral LD 50 > 5000 mg/kg
- Mouse Oral LD 50 > 3000mg/kg
- Rat Intraperitoneal LD 50 404-488mg/kg
- Mouse Intraperitoneal LD 50 396-419mg/kg

Magnesium stearate
- Rat Oral LD50 > 2000 mg/kg
- Rat Inhalation LC50 > 2000 mg/m³

Mannitol
- Rat Oral LD 50 13500 mg/kg
- Mouse Oral LD 50 22 g/kg

Microcrystalline cellulose
- Rat Oral LD50 > 5000 mg/kg
- Rabbit Dermal LD50 > 2000 mg/kg
11. TOXICOLOGICAL INFORMATION

**Polysorbate 80**
- Rat Oral LD50 25 g/kg

**Sucrose**
- Rat Oral LD50 29.7 g/kg

**Hydroxypropyl methylcellulose**
- Rat Oral LD50 > 10,000 mg/kg

**Titanium dioxide**
- Rat Oral LD50 > 7500 mg/kg
- Rat Subcutaneous LD50 50 mg/kg

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

**Irritation / Sensitization: (Study Type, Species, Severity)**

**Exemestane**
- Eye Irritation Rabbit Minimal
- Skin Irritation Rabbit Non-irritating
- Skin Sensitization - M & K Guinea Pig Negative

**Microcrystalline cellulose**
- Skin Irritation Rabbit Non-irritating
- Eye Irritation Rabbit Non-irritating

**Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)**

**Exemestane**
- 4 Week(s) Rat Oral 150 mg/kg/day NOAEL None identified
- 4 Week(s) Rat Oral 1000 mg/kg/day LOAEL Liver, Thymus, Spleen, Reproductive system
- 4 Week(s) Dog Oral 30 mg/kg/day LOAEL Reproductive system
- 13 Week(s) Mouse Oral 30 mg/kg/day LOAEL Reproductive system
- 26 Week(s) Rat Oral 30 mg/kg/day LOAEL Female reproductive system

**Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))**

**Exemestane**
- Reproductive & Fertility-Males Rat Oral 500 mg/kg/day LOAEL Fertility
- Fertility and Embryonic Development Rat Oral 20 mg/kg/day LOAEL Fetotoxicity
- Fertility and Embryonic Development Rat Oral 215 mg/kg/day LOAEL Fertility, Fetotoxicity
- Embryo / Fetal Development Rat Oral 10 mg/kg/day LOAEL Developmental toxicity
- Embryo / Fetal Development Rabbit Oral 30 mg/kg/day LOAEL Developmental toxicity

**Genetic Toxicity: (Study Type, Cell Type/Organism, Result)**

**Exemestane**
- Bacterial Mutagenicity (Ames) *Salmonella, E. coli* Negative
11. TOXICOLOGICAL INFORMATION

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Exemestane
2 Year(s)  Rat Oral  315 mg/kg/day  NOAEL  Not carcinogenic
2 Year(s)  Mouse Oral  150 mg/kg/day  LOAEL  Tumors, Liver, Kidneys

Carcinogen Status:  See below

Silica colloidal, Ph. Eur.
IARC:  Group 3 (Not Classifiable)

Cros piv odone
IARC:  Group 3 (Not Classifiable)

Polyvinyl alcohol
IARC:  Group 3 (Not Classifiable)

Titanium dioxide
IARC:  Group 2B (Possibly Carcinogenic to Humans)

12. ECOLOGICAL INFORMATION

Environmental Overview:  In the environment, the active ingredient in this formulation is expected to remain in water or migrate through the soil to groundwater. Harmful effects to aquatic organisms could occur.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Exemestane
*Pseudokirchneriella subcapitata* (Green Alga)  OECD  EC50  72 Hours  7.1 mg/L
*Oncorhynchus mykiss* (Rainbow Trout)  OECD  LC50  96 Hours  2.8 mg/L

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Exemestane
*Nostoc sp.* (Freshwater Cyanobacteria)  TAD  MIC  40 mg/L

Persistence and Degradability:

Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)

Exemestane
OECD  Activated sludge  Ultimate (CO2 Evolution)  15.21% After 28 Day(s)  Not Ready

Bio-accumulative Potential:
Partition Coefficient: (Method, pH, Endpoint, Value)
Exemestane
Measured 7 Log P 2.5

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Exemestane
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
- EU EINECS/ELINCS List: Not Listed

Silica colloidal, Ph. Eur.
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Australia (AICS): Present
- EU EINECS/ELINCS List: Not Listed

Crospovidone
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
### 15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>Material Name</th>
<th>CERCLA/SARA 313 Emission reporting</th>
<th>California Proposition 65</th>
<th>Inventory - United States TSCA - Sect. 8(b)</th>
<th>Australia (AICS)</th>
<th>EU EINECS/ELINCS List</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hygroxypropyl methylcellulose</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td>Not Listed</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td>209-150-3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mannitol</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td>200-711-8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td>232-674-9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylparaben</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td>202-785-7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Macrogol 6000</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polysorbate 80</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Revision date: 29-May-2018
15. REGULATORY INFORMATION

Australia (AICS):
- EU EINECS/ELINCS List: Present

Polyvinyl alcohol
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: Not Listed

Sodium starch glycolate
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: Not Listed

Sucrose
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- REACH - Annex IV - Exemptions from the obligations of Register:
  - EU EINECS/ELINCS List: 200-334-9

Simethicone emulsion
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: Not Listed

Titanium dioxide
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: carcinogen 9/2/2011 airborne, unbound particles of respirable size
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 236-675-5

Magnesium carbonate
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Australia (AICS): Present
- EU EINECS/ELINCS List: Not Listed

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3
Reproductive toxicity-Cat.1B; H360FD - May damage fertility. May damage the unborn child.
Hazardous to the aquatic environment, acute toxicity-Cat.2; H401 - Toxic to aquatic life
Hazardous to the aquatic environment, chronic toxicity-Cat.2; H411 - Toxic to aquatic life with long lasting effects

Data Sources: 
Pfizer proprietary drug development information. Publicly available toxicity information. Safety data sheets for individual ingredients.

Reasons for Revision:
Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 8 - Exposure Controls / Personal Protection.

Prepared by: 
Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet